Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.1%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price dropped 4.1% during trading on Monday . The stock traded as low as $24.75 and last traded at $24.75. Approximately 33,807 shares traded hands during trading, a decline of 77% from the average daily volume of 144,789 shares. The stock had previously closed at $25.80.

Analyst Ratings Changes

DNTH has been the subject of a number of research analyst reports. Jefferies Financial Group increased their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Wedbush upped their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Stifel Nicolaus started coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 price objective on the stock. Finally, Raymond James raised their price target on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $42.40.

Dianthus Therapeutics Stock Performance

The stock has a 50 day moving average of $25.56 and a 200 day moving average of $18.02.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $28,961,000. Acadian Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics in the third quarter worth $303,000. Atlas Venture Life Science Advisors LLC purchased a new position in Dianthus Therapeutics during the 3rd quarter valued at about $3,240,000. Avidity Partners Management LP purchased a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $16,644,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $497,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.